Data from: Mistletoe host diversity decreases with elevation in a temperate rainforest of southern Chile: implications for frugivory by Victoria P. Fernández (11989404)

“…<p dir="ltr">Original data from:</p><p dir="ltr">Fontúrbel, F.E., J.I. Orellana, Fernández, V.P., G.C. Amico & R.F. …”

MEK1/2 inhibition promotes invasive-opposing leading edge lamellipodial structures in 3-D by increasing localised Rac1 activity and decreasing localised RhoA activity. by Joseph H. R. Hetmanski (2656735)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Comparison of the Th2 cytokine expression level after treatment with KA/E2 in WT and TLR2 KO mice. by Mi-Kyung Park (56053)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Lansoprazole decreases IL-4-stimulated eotaxin-3 protein secretion in (A) EoE1-T and (2) EoE2-T cells. by Xi Zhang (83736)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Effect of 1N11 on cultured endothelial cell migration impairment by 3F8 or aPL, and on aPL blunting of carotid artery reendothelialization in vivo. by Chieko Mineo (725831)

Subjects:

IFN-β mRNA induction but IFN protein decrease in all mammalian cells upon ONNV infection. by Susanne E. Biesold (194461)

“…(E) Comparison of mRNA fold-induction of IFN stimulated genes (<i>MxA</i> and <i>ISG56</i>) to secreted IFN protein at time points 0 hpi and 24 hpi. …”

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)